Skip to main content
Premium Trial:

Request an Annual Quote

Quark, Biocon to Collaborate on RNAi Drug Development in India

Premium

Quark Pharmaceuticals and Indian biotech firm Biocon announced this week that they have formed a partnership to develop and market siRNA-based drugs.

Under the deal, Biocon will have access to Quark's RNAi technology and knowhow to create novel drugs for the Indian market, as well as certain other undisclosed territories.

Biocon will also be able to co-develop and sell Quark's investigational glaucoma treatment QPI-1007 in those areas. The drug recently completed a phase I/IIa trial in a related condition called non-arteritic anterior ischemic optic neuropathy.

Additional terms of the arrangement were not disclosed.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.